Main Article Content
Background: HIV/AIDS causes life threatening opportunistic infections with increased morbidity and mortality. HAART intervention in HIV/AIDS patients has not only reduce morbidity and mortality but also cause hepatic injury and elevation of the liver enzymes.
Aim: To measure the liver enzymes in HIV/AIDS patients on highly active antiretroviral therapy (HAART) and HIV/AIDS negative subjects.
Methodology: Seventy patients aged 20-50 years with asymptomatic HIV seropositive infection on HAART, 39 of whom are on first line drug and 31 on second line drug were assessed and 30 apparently healthy subjects (control) that tested negative for HIV 1 and 2 were recruited into this study. Venous blood was collected to determine the plasma levels of ALT, AST and ALP using kinetic method. Data were statistically analyzed using paired t-tests, P<0.05 was considered as statistically significant.
Result: The activities of serum ALT and AST observed in HIV infected asymptomatic patients on HAART (first line and second line drug) were significantly higher (P<0.001) than in the HIV negative (control) group. No significant difference was observed in ALP of HIV infected asymptomatic patient on HAART (those on second line drug) P>0.05 while there was a significant difference in those on first line drug (P=0.0058) when compared with the control.
Conclusion: Management of HIV/AIDS patients with HAART should be done with caution because hepatic injury may ensue due to the HAART.
Brooks GF, Carnoll KC, Janet S, Butel Morse SA, Mietne TA. Jawetz, melnicks adelberg’s medical microbiology. McGraw-Hill Companies North American. 25th Edition. 2010;406-407.
Rehana Basri and Wan Mohamad Wan Majdiah. Neurological manifestations of HIV-1 infection and markers for HIV progression, current perspectives in HIV infection, Shailendra K. Saxena, Intech Open; 2013.
Nigerian HIV/AIDS Indicator and Impact Survey NAIIS. National Summary Sheet Preliminary Findings; 2019.
Neff GW, Jayaweera D, Sherman KE. Drug-induced liver injury in HIV patients gastroenterology & hepatology. 2006;2(6): 430–437.
Núñez M, Lana R, Mendoza J, Martín-Carbonero L, Soriano V. Risk factors for severe hepatic injury following the introduction of HAART. Journal of Acquired Immune Defficiency Syndrome. 2001;27: 426–431.
Neff GW, O’Brien C, Montalbano M. Consumption of dietary supple¬ments in a liver transplant population. Liver Trans-plant. 2004;10:881-885.
Núñez M, Lana R, Mendoza J, Martín-Carbonero L, Soriano V. Risk factors for severe hepatic injury following the introduction of HAART. Journal of Acquired Immune Defficiency Syndrome Syndr. 2001;27:426–431.
Shiferaw MB, Ketema TT, Zegeye AM, Wubante AA. Liver enzyme abnormalities among highly active antiretroviral therapy experienced and HAART naïve HIV-1 infected patients at Debre Tabor Hospital, North West Ethiopia: A comparative cross-sectional study. AIDS Research and Treatment. 2016;7.
Huang Xing-Jiu, Choi Yang-Kyu, Im Hyung-Soon, Yarimaga Oktay, Yoon Euisik, Kim Hak-Sung. Aspartate amino-transferase (AST/GOT) and alanine aminotransferase (ALT/GPT) detection techniques sensors. 2006;6:756-782.
Burtis CA, Ashwood ER. Clinical chemistry. 3rd Edition; 1999.
Wit FWNM, Weverling GJ, Weel J, Jurriaans S, Lange JMA. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combina¬tion therapy. J Infect Dis. 2002;186:23-31.
den Brinker M, Wit FW, Wertheim-van Dillen. PM Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895-2902.
Maduka C, Ignatius E, Neboh E, Ikekpeazu EJ, Ureme S, Umeh C, Ejezie E. Assessment of liver enzymes in asymptomatic HIV-seropositive patients. Research Journal of Biological Sciences. 2009;4(3):360-362.